<DOC>
	<DOCNO>NCT01790100</DOCNO>
	<brief_summary>The purpose study determine safety , pharmacokinetics efficacy orally administer VX-135 ribavirin treatment naive subject chronic hepatitis C infection .</brief_summary>
	<brief_title>A Phase 2a , Dose-Ranging Study Evaluate Safety , Pharmacokinetics Efficacy VX-135 With Ribavirin Treatment-Na√Øve Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description>Up twenty ( 20 ) subject CHC GT1 infection randomize 1:1 ratio ( stratification IL-28B genotype ( CC versus non-CC ) ) evaluate VX-135 low dose high dose give combination RBV 12 week . Safety tolerability evaluate ongoing basis assessment adverse event ( AEs ) , lab evaluation physical examination . Subjects monitor Day 1 end follow-up virologic breakthrough relapse .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Key Subjects ( male female ) must 1860 year age Subjects must Chronic Hepatitis C Subjects must treatment naive Subjects must laboratory value screen within limit specify protocol Key Evidence cirrhosis Female subject pregnant nurse male subject female partner childbearing potential unwilling adhere contraception requirement , pregnant nursing , plan become pregnant study cause significant liver disease addition hepatitis C Diagnosis suspect hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>